1Rosen CJ,Kessenich CR.Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases[J].Drugs,1996,51(4): 537. 被引量：1
2Fleisch H.Bisphosphonates: pharmacology and use in the treatment of tumour- induced hypercalcaemic and metastatic bone disease[J].Drugs,1991,42: 919. 被引量：1
3Compston JE.The therapeutic use of bisphosphonates[J].Bri Med J,1994,309(6 956): 711. 被引量：1
4Anonymous.Useful role for bisphosphonates in cancer- related bone disease[J].Drugs Ther Perspect,1995,5(4): 1. 被引量：1
7Urwin GH,Yates AJP.Treatment of the hypercalcaemic of malignancy with intravenous clodronato[J].Bone,1997,8(Suppl 1): 43. 被引量：1
8Clarke NW,Holbrook IB,Mc Clure J,et al.Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study[J].Br J Cancer,1991,63: 420. 被引量：1
9Carano A,Teitelbaum SL,Konsek JD,et al.Bisphosph- onates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro[J].J Clin Inrest,1990,85(2): 456. 被引量：1
10Pluijm GVD,Binderup L,Bramn E,et al.Disodium 1- hy- droxy- 3- (1- pyrrolidinyl)- propylidene- 1,1- bi- sphosphonate(EB- 1053)is a potent inhibitor of bone resorption in vitro and in vivo[J].J Bone Miner Res,1992,7(8): 981. 被引量：1
8Coleman RE, Woll PJ. MiLes. Metal Treatment of bone metastases from breast cancer with. 3-amino-l -hydroxy, propylidene) -1-1-bisphosphonate (APD) Br J Cancer, 1988,58: 621. 被引量：1
